Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 6391 AL 6405

Novel aβ isoforms in Alzheimer's disease - their role in diagnosis and treatment

Portelius E, Mattsson N, Andreasson U, Blennow K, Zetterberg H.

Curr Pharm Des. 2011;17(25):2594-602. doi: 10.2174/138161211797416039.

Fluorodeoxyglucose positron emission tomography: emerging roles in the evaluation of putative Alzheimer's disease-modifying treatments

Reiman EM; Alzheimer's Disease Biomarkers Working Group for the Alliance for Aging Research.

Neurobiol Aging. 2011 Dec;32 Suppl 1(Suppl 1):S44-7. doi: 10.1016/j.neurobiolaging.2011.09.007. Epub 2011 Oct 7.

Clinical trial methodologies for disease-modifying therapeutic approaches

Aisen PS.

Neurobiol Aging. 2011 Dec;32 Suppl 1(Suppl 1):S64-6. doi: 10.1016/j.neurobiolaging.2011.09.008. Epub 2011 Oct 8.

Aβ-degrading enzymes: potential for treatment of Alzheimer disease

Miners JS, Barua N, Kehoe PG, Gill S, Love S.

J Neuropathol Exp Neurol. 2011 Nov;70(11):944-59. doi: 10.1097/NEN.0b013e3182345e46.

CSF biomarkers for amyloid and tau pathology in Alzheimer's disease

Rosenmann H.

J Mol Neurosci. 2012 May;47(1):1-14. doi: 10.1007/s12031-011-9665-5. Epub 2011 Nov 5.

Risk-takers wanted

Nat Med. 2011 Nov 7;17(11):1321. doi: 10.1038/nm.2573.

Molecular PET imaging in multicenter Alzheimer's therapeutic trials: current trends and implementation strategies

Seibyl J, Zubal IG, Jennings D, Marek K, Doraiswamy PM.

Expert Rev Neurother. 2011 Dec;11(12):1783-93. doi: 10.1586/ern.11.168.

Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia

Klunk WE.

Neurobiol Aging. 2011 Dec;32 Suppl 1(Suppl 1):S20-36. doi: 10.1016/j.neurobiolaging.2011.09.006.

Alliance for aging research AD biomarkers work group: structural MRI

Jack CR Jr.

Neurobiol Aging. 2011 Dec;32 Suppl 1(0 1):S48-57. doi: 10.1016/j.neurobiolaging.2011.09.011.

Pentraxins and Alzheimer's disease: at the interface between biomarkers and pharmacological targets

Osera C, Pascale A, Amadio M, Venturini L, Govoni S, Ricevuti G.

Ageing Res Rev. 2012 Apr;11(2):189-98. doi: 10.1016/j.arr.2011.12.004. Epub 2011 Dec 15.

The potential role of microRNA-146 in Alzheimer's disease: biomarker or therapeutic target?

Wang LL, Huang Y, Wang G, Chen SD.

Med Hypotheses. 2012 Mar;78(3):398-401. doi: 10.1016/j.mehy.2011.11.019. Epub 2011 Dec 29.

Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets

Lee VM, Brunden KR, Hutton M, Trojanowski JQ.

Cold Spring Harb Perspect Med. 2011 Sep;1(1):a006437. doi: 10.1101/cshperspect.a006437.

C-peptide and its correlation to parameters of insulin resistance in the metabolic syndrome

Banu S, Jabir NR, Manjunath CN, Shakil S, Kamal MA.

CNS Neurol Disord Drug Targets. 2011 Dec;10(8):921-7. doi: 10.2174/187152711799219271.

New roles for insulin-like hormones in neuronal signalling and protection: new hopes for novel treatments of Alzheimer's disease?

Hölscher C, Li L.

Neurobiol Aging. 2010 Sep;31(9):1495-502. doi: 10.1016/j.neurobiolaging.2008.08.023. Epub 2008 Oct 18.

Comparison of recruitment efforts targeted at primary care physicians versus the community at large for participation in Alzheimer disease clinical trials

Carr SA, Davis R, Spencer D, Smart M, Hudson J, Freeman S, Cooper GE, Schmitt FA, Markesbery WR, Danner D, Jicha GA.

Alzheimer Dis Assoc Disord. 2010 Apr-Jun;24(2):165-70. doi: 10.1097/WAD.0b013e3181aba927.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias